CASES OF DIFFUSE LARGE B-CELL LYMPHOMA WITH FUNCTIONAL INTRON MUTATIONS IN THE TP53 GENE
https://doi.org/10.21294/1814-4861-2020-19-1-134-140
Abstract
Background. the presence of functionally significant intron mutations in the TP53 gene was demonstrated in experiments in vitro and on samples of patients with some variants of non-Hodgkin’s lymphomas. to date, the studies of TP53 in tumor tissue of patients with diffuse large B-cell lymphoma (dlBCl) have been focused on the mutations in 5–8 exons of the gene. For these reasons, further studies of the spectrum of changes in the intron sequences of the TP53 gene and the determination of their functional effect in dlBCl are required.
Description. We present two case reports that are of interest as the cases for detection of functionally significant intron TP53 mutations in dlBCl tissue, first published in the Russian scientific literature. the first clinical case of dlBCl was clinically characterized by extranodal tumor at the onset of the disease, severe symptoms of tumor intoxication, high paraclinical tumor activity, and early hemoblastosis recurrence. the second case of dlBCl was characterized by initially massive tumor lesion, rapidly progressive course of the disease, severe symptoms of tumor intoxication, high paraclinical tumor activity and poor response to therapy with subsequent generalization of lymphoma.
Conclusion. Mutations in the TP53 gene are the driver of the tumor process, serve not only as a marker of aggressive tumor progression, but also as an independent predictor of reduced sensitivity to treatment. the presented clinical cases show that an in-depth analysis of the results of the TP53 sequencing in tumors and functional assessment of all detected changes, including changes in the introns of the gene and involving in silico analysis techniques, are necessary.
Supporting agencies: The work was carried out within the framework of the Budget theme on the State task No. 0324-2018-0002
About the Authors
E. N. Voropaeva
Research Institute of Internal and Preventive Medicine Branch of the Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences
Russian Federation
Russian Federation
MD, DSc, Senior Researcher, Laboratory of Molecular Genetic Studies of Therapeutic Diseases
Researcher ID (WOS): A-5360-2014. Author ID (Scopus): 36020818100
175/1, B. Bogatkova street, novosibirsk, 630089, Russia
M. I. Voevoda
Research Institute of Internal and Preventive Medicine –Branch of the Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences
Russian Federation
Russian Federation
MD, Member of the Russian Academy of Sciences, Professor, Director
Researcher ID (WOS): N-6713-2015. Author ID (Scopus): 7004003785
175/1, B. Bogatkova street, novosibirsk, 630089, Russia
T. I. Pospelova
Novosibirsk State Medical University of the Russian Ministry of Health
Russian Federation
Russian Federation
MD, Professor, Head of the Department of Therapy, Hematology and Transfusiology
Author ID (Scopus): 7005792562
52, Krasny Prospect, novosibirsk, 630091, Russia
V. N. Maksimov
Research Institutе of Internal and Preventive Medicine Branch of the Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences
Russian Federation
Russian Federation
MD, Professor, Head of the Laboratory of Molecular-genetic Methods for the Study of Therapeutic Diseases
Researcher ID (WOS): H-7676-2012. Author ID (Scopus): 7202540327
175/1, B. Bogatkova street, novosibirsk, 630089, Russia
References
1. Xu-Monette Z.Y., Wu L., Visco C., Tai Y.C., Tzankov A., Liu W.M., Montes-Moreno S., Dybkaer K., Chiu A., Orazi A., Zu Y., Bhagat G., Richards K.L., Hsi E.D., Zhao X.F., Choi W.W., Zhao X., van Krieken J.H., Huang Q., Huh J., Ai W., Ponzoni M., Ferreri A.J., Zhou F., Kahl B.S., Winter J.N., Xu W., Li J., Go R.S., Li Y., Piris M.A., Møller M.B., Miranda R.N., Abruzzo L.V., Medeiros L.J., Young K.H. Mutational profile and prognostic significance of TP53 in diffuse large B-celllymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012 Nov 8; 120(19): 3986–96. doi: 10.1182/blood-2012-05-433334.
2. Young K.H., Weisenburger D.D., Dave B.J., Smith L., Sanger W., Iqbal J., Campo E., Delabie J., Gascoyne R.D., Ott G., Rimsza L., MüllerHermelink H.K., Jaffe E.S., Rosenwald A., Staudt L.M., Chan W.C., Greiner T.C. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood. 2007 Dec 15; 110(13): 4396–405. doi: 10.1182/blood-2007-02-072082.
3. Tamimi Y., Al-Harthy S., Al-Haddabi I., Al-Kindi M., Babiker H., AlMoundhri M., Burney I. The p53 mutation/deletion profle in a small cohort of the Omani population with Diffuse Large B-Cell Lymphoma. Sultan Qaboos Univ Med J. 2014 Feb; 14(1): e50–8. doi: 10.12816/0003336.
4. Bouaoun L., Sonkin D., Ardin M., Hollstein M., Byrnes G., Zavadil J., Olivier M. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat. 2016 Sep; 37(9): 865–76. doi: 10.1002/humu.23035.
5. Leroy B., Fournier J.L., Ishioka C., Monti P., Inga A., Fronza G., Soussi T. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2013 Jan; 41(Database issue): D9629. doi: 10.1093/nar/gks1033.
6. Sondka Z., Bamford S., Cole C.G., Ward S.A., Dunham I., Forbes S.A. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018 Nov; 18(11): 696–705. doi: 10.1038/s41568-018-0060-1.
7. Stenson P.D., Mort M., Ball E.V., Evans K., Hayden M., Heywood S., Hussain M., Phillips A.D., Cooper D.N. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017 Jun; 136(6): 665–677. doi: 10.1007/s00439-017-1779-6.
8. Charbonneau B., Maurer M.J., Fredericksen Z.S., Zent C.S., Link B.K., Novak A.J., Ansell S.M., Weiner G.J., Wang A.H., Witzig T.E., Dogan A., Slager S.L., Habermann T.M., Cerhan J.R. Germline variation in complement genes and event-free survival in Follicular and Diffuse Large B-Cell Lymphoma. Am J Hematol. 2012 Sep; 87(9): 880–5. doi: 10.1002/ajh.23273.
9. Voropaeva E.N., Voevoda M.I., Pospelova T.I., Maksimov V.N. Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients. Br J Haematol. 2015 Apr; 169(1): 32–5. doi: 10.1111/bjh.13237.
10. Senturk S., Yao Z., Camiolo M., Stiles B., Rathod T., Walsh A.M., Nemajerova A., Lazzara M.J., Altorki N.K., Krainer A., Moll U.M., Lowe S.W., Cartegni L., Sordella R. P53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci USA. 2014 Aug 12; 111(32): E3287–96. doi: 10.1073/pnas.1321640111.
11. Lehman T.A., Haffty B.G., Carbone C.J., Bishop L.R., Gumbs A.A., Krishnan S., Shields P.G., Modali R., Turner B.C. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res. 2000 Feb 15; 60(4): 1062–9.
12. Hillebrandt S., Streffer C., Demidchik E.P., Biko J., Reiners C. Polymorphisms in the p53 gene in thyroid tumors and blood samples of children from areas in Belarus. Mutat Res. 1997; 381(2): 201–7. doi: 10.1016/s0027-5107(97)00169-3.
13. Kitts A., Phan L., Ward M., Holmes J.B. The Database of Short Genetic Variation (dbSNP) [Internet]. URL: https://www.ncbi.nlm.nih.gov/books/NBK174586 (cited 26.02.2019).
14. Brunak S., Engelbrecht J., Knudsen S. Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol. 1991 Jul 5; 220(1): 49–65. doi: 10.1016/0022-2836(91)90380-o.
15. Marcel V., Dichtel-Danjoy M.L., Sagne C., Hafsi H., Ma D., OrtizCuaran S., Olivier M., Hall J., Mollereau B., Hainaut P., Bourdon J.C. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ. 2011; 18(12): 1815–24. doi: 10.1038/cdd.2011.120.
16. Yabas M., Elliott H., Hoyne G.F. The role of alternative splicing in the control of immune homeostasis and cellular differentiation. Int J Mol Sci. 2015 Dec 22; 17(1). pii: E3. doi: 10.3390/ijms17010003.
17. Diederichs S., Bartsch L., Berkmann J.C., Fröse K., Heitmann J., Hoppe C., Iggena D., Jazmati D., Karschnia P., Linsenmeier M., Maulhardt T., Möhrmann L., Morstein J., Paffenholz S.V., Röpenack P., Rückert T., Sandig L., Schell M., Steinmann A., Voss G., Wasmuth J., Weinberger M.E., Wullenkord R. The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, noncoding RNA and synonymous mutations. EMBO Mol Med. 2016 May 2; 8(5): 442–57. doi: 10.15252/emmm.2015060
Review
For citations:
Voropaeva E.N., Voevoda M.I., Pospelova T.I., Maksimov V.N. CASES OF DIFFUSE LARGE B-CELL LYMPHOMA WITH FUNCTIONAL INTRON MUTATIONS IN THE TP53 GENE. Siberian journal of oncology. 2020;19(1):134-140. (In Russ.) https://doi.org/10.21294/1814-4861-2020-19-1-134-140
Views:
1260
Email this article 
